RT-111
Inflammatory Diseases (Ustekinumab Biosimilar)
Phase 1Active - Phase 1 results reported
Key Facts
Indication
Inflammatory Diseases (Ustekinumab Biosimilar)
Phase
Phase 1
Status
Active - Phase 1 results reported
Company
About Rani Therapeutics
Rani Therapeutics has developed a disruptive technology platform, the RaniPill™, designed to enable the oral delivery of biologic drugs that currently require injection. The company has demonstrated high reliability, safety, and bioavailability comparable to subcutaneous injections in multiple preclinical and clinical studies. Its mission is to improve patient compliance and quality of life for millions with chronic conditions by eliminating the need for needles. Rani is advancing a pipeline of oral biologics, with lead candidates showing promising Phase 1 results in osteoporosis and inflammatory diseases.
View full company profile